Clinical trial

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

NCT06618014

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Toripalimab Normalized identity: toripalimabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-01-11

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Interventions

ToripalimabDRUG · verified · RxNorm: toripalimab

DocetaxelDRUG · verified · RxNorm: docetaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06618014 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.